Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
EHRA 24: A Substudy of NOAH-AFNET 6
Author(s): Julius Nikorowitsch Added: 1 year ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from… View more

Electrophysiology & Arrhythmia
ESC 23: MULTISTARS AMI Trial
Author(s): Linda Joosten Added: 1 year ago
ESC 2023 — Dr Linda Joosten (Julius Center for Health Sciences and Primary Care, NL) joins us to discuss the findings of the FRAIL-AF trial. FRAIL-AF is a multicentre, open-label randomised controlled clinical trial which studied frail elderly patients who receive vitamin K antagonist (VKA) treatment for atrial fibrillation (AF). Current clinical guidelines recommend non-vitamin K antagonists … View more

Anticoagulation

Demographic
AHA 24: The OPTION Trial
Author(s): Oussama M Wazni Added: 5 months ago
AHA Conference 2024 - Safety and efficacy outcomes comparing left atrial appendage (LAA) closure with the WATCHMAN FLX device to oral anticoagulation (OAC) following atrial fibrillation (AF) catheter ablation.Dr Oussama Wazni (The Cleveland Clinic Foundation, Ohio, US) joins us onsite at AHA Conference to discuss the findings from OPTION (NCT03795298).OPTION is a prospective, multi-center, multi… View more

Anticoagulation

Electrophysiology & Arrhythmia
ESC 23: The PUSH-AHF Study
Author(s): Paulus Kirchhof Added: 1 year ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577). NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,… View more

Anticoagulation

Heart Failure
ESC 23: The RIGHT Study
Author(s): Yan Yan , Gilles Montalescot Added: 1 year ago
ESC 23 — Dr Yan Yan (Beijing Anzhen Hospital, CN) and Prof Gilles Montalescot (Pitie Salpetriere APHP University Hospital,FR) discusses the findings from a comparison of anticoagulation prolongation vs no anticoagulation in STEMI patients post-primary PCI (RIGHT) (NCT03664180). The RIGHT study (Beijing Anzhen Hospital) aimed to evaluate the clinical efficacy and safety of anticoagulation… View more

Anticoagulation

MI/ACS
ESC 24: The POPular PAUSE TAVI Trial
Author(s): Dirk-Jan van Ginkel Added: 8 months ago
ESC Congress 2024 — No benefit of continuing oral anticoagulation during TAVI procedure.Investigator, Dr Dirk-Jan van Ginkel (St Antonius Hospital, NL) joins us to discuss the result of the POPular PAUSE TAVI trial (NCT04437303; St Antonius Hospital). Presented for the first time at ESC 2024, this multicenter, randomized, open-label clinical trial compared the safety and efficacy of continuous… View more

Anticoagulation

Prevention & Chronic Conditions
ESC 23: The ONCO DVT Study
Author(s): Yugo Yamashita Added: 1 year ago
ESC 23 — In this concise interview, Dr Yugo Yamashita (Kyoto University Graduate School of Medicine, JP) reveals the findings of the ONCO DVT Study (NCT03895502). The ONCO DVT study (Takeshi Morimoto) aimed to determine the ideal duration of anticoagulation therapy with the direct oral anticoagulant (DOAC) edoxaban for the treatment of isolated distal deep vein thrombosis (IDDVT) in patients… View more

Anticoagulation

Vascular Disease and Surgery
Research Area(s) / Expertise:
Prof. Ken Okumura served as a Professor of Medicine at Hirosaki University School of Medicine from 1996 to 2016. He also served as a President of the Japanese Heart Rhythm Society (JHRS) from 2012 to 2016. He is now working at Saiseikai Kumamoto Hospital Cardiovascular Center, Japan, while providing the latest interventional treatments for cardiac arrhythmias especially catheter ablation of AF… View more
Author(s): Finn Gustafsson Added: 1 year ago
HFA 24 - Dr Finn Gustafsson (Rigshospitalet, DK) joined us onsite at the Heart Failure Association Congress to discuss the findings from a subanalysis of the ARIES HeartMate 3 study (NCT04069156).ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two… View more

Anticoagulation

Heart Failure